Viatris Securities Fraud Lawsuit
Analysis based on 28 articles · First reported Apr 07, 2025 · Last updated May 15, 2025
The lawsuit against Viatris for alleged securities fraud, stemming from a failed United States — Food and Drug Administration inspection at its India facility, has led to a significant decline in Viatris's stock price. This event highlights regulatory risks in the pharmaceutical industry and could lead to increased scrutiny of other companies' manufacturing practices, potentially affecting investor confidence in the sector.
Viatris, a global healthcare company, is facing a securities fraud lawsuit filed by Bleichmar Fonti & Auld LLP. The lawsuit alleges that Viatris made misleading statements about the operational condition of its facilities. This came to light after the United States — Food and Drug Administration issued a Warning Letter on December 23, 2024, following a failed inspection at Viatris's Indore, India, facility. Despite Viatris initially downplaying the situation, the ramifications were significant, preventing the manufacturing and distribution of key products like Lenalidomide. On February 27, 2025, Viatris disclosed that the failed inspection would negatively impact its 2025 revenue by approximately $500 million and earnings by approximately $385 million. This news caused Viatris's stock price to decline by roughly 15% in a single trading day.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard